Over the past 8 years, Emily has held a number of roles in drug discovery program management. Her first was at the Novartis Drug Discovery Incubator within Novartis Institutes for Biomedical Research. This group sought to internally “partner” high-risk discovery programs within Novartis for full clinical development. Subsequently, Emily was responsible for business, financial, alliance and scientific program management across a number of research and development programs at Alnylam Pharmaceuticals. After Alnylam, Emily founded Tremont Therapeutics, a small virtual biotech focused on identifying and developing promising therapeutics from academia from mid-discovery through human proof of concept. Since 2011, Emily has served as a drug development and program management consultant for a range of clients from early startups to big pharma.